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Systemic cytokine activity in response to Toll-like
receptor (TLR) signaling induces the expression of
various proteins in the liver after infections. Here we
show that Interleukin-7 (IL-7), the production ofwhich
was thought to occur at a constant rate in vivo, was
a hepatically expressed protein that directly con-
troled T cell responses. Depletion of IL-7 expression
in the liver abrogated several TLR-mediated T cell
events, including enhanced CD4+ T cell and CD8+
T cell survival, augmented CD8+ T cell cytotoxic
activity, and the development of experimental auto-
immune encephalitis, a Th17 cell-mediated autoim-
mune disease. Thus, T cell responses are regulated
by hepatocyte-derived IL-7, which is expressed in
response to TLR signaling in vivo. We suggested
that TLR-induced IL-7 expression in the liver, which
is an acute-phase response, may be a good diag-
nostic and therapeutic target for efficient vaccine
developments and for conditions characterized by
TLR-mediated T cell dysregulation, including autoim-
mune diseases.
INTRODUCTION
Conserved microbial structures associated with bacterial and
viral infections are locally recognized by Toll-like receptors
(TLRs), which then can induce both innate and adaptive immune
responses (Janeway and Medzhitov, 2002). For example, after
lipopolysaccharide (LPS) binds its receptor, TLR4, at least two
signaling pathways are activated; one is dependent on the
adaptor protein, myeloid differentiation primary response gene
88 (Myd88), whereas the other is mediated by other adaptor,
Toll/IL-1 receptor domain-containing adaptor inducing IFN-
beta (TRIF), Toll-like receptor adaptor molecule 1 (Ticam1)
(Yamamoto et al., 2003; Hoebe et al., 2003). Myd88, a TLR-
binding protein, contributes to the LPS-induced activation of
the transcriptional factor, NF-kB and mitogen-activated protein
kinases, thereby inducing inflammation. On the other hand,
TRIF-dependent signaling via the TLR4 receptor leads to the
activation of interferon regulatory factor 3 (IRF3) and subsequent
type I interferon (IFN-I) expression (Yamamoto et al., 2003).TLR-mediated signals in a variety of inflammatory cells,
including dendritic cells, macrophages, neutrophils, and nonhe-
matopoietic cells, result in the production of proinflammatory
cytokines, such as interleukin-1 (IL-1), IL-6, TNF-a, IFN-a and -b,
and IFN-g (Takeda et al., 2003). These cytokines initiate various
systemic responses and ‘‘acute-phase reactions,’’ which are
characterized by altered protein expression profiles in hepato-
cytes, including the production of such serum proteins as serum
amyloid A (SAA), C-reactive protein (CRP), plasminogen, ferritin,
and complement components (Fey et al., 1994), suggesting that
the liver is a sensor of inflammation.
Interleukin-7 (IL-7), which is known to be important for T cell
homeostasis, is mainly produced by stromal cells (Marrack
et al., 2000). It is believed that the production of IL-7 in stromal
cells occurs at a constant rate in vivo and is unaffected by most
extrinsic stimuli (Ma et al., 2006; Mazzucchelli and Durum,
2007). Alternatively, several reports using cell lines have demon-
strated that IL-7 expression is induced in vitro by IFN-g and
inhibited by TGF-b (Ariizumi et al., 1995; Tang et al., 1997). Never-
theless, IL-7 expression in vivo, which appears to limit the size of
the lymphocyte pool, is thought to be regulated by IL-7 receptor
a (IL-7Ra)-mediated consumption rather than the rate of IL-7
expression (Mazzucchelli and Durum, 2007). Indeed, the expres-
sion of IL-7Ra varies during the development of T and B cells
(Mazzucchelli and Durum, 2007). Moreover, IL-7Ra expression
in mature T cells can be regulated by extrinsic stimuli, including
antigens and cytokines (Schluns et al., 2000). We, however,
showed that excessive IL-6 signaling increased the amount of
IL-7 expression in vivo, which was followed by the development
of autoimmune arthritis (Sawa et al., 2006). Thus, whether IL-7
expression can be influenced by external stimuli, including
TLR-mediated stimulation, requires further elucidation in vivo.
Here, we show that IL-7 expression induced in the liver in
response to TLR signaling regulated T cell responses in vivo.
This process likely controls a range of physiologic and patho-
logic responses by enhancing T cell survival.
RESULTS
IL-7 Expression in Hepatocytes Is Induced by LPS
Injection In Vivo
We previously demonstrated that hyperactivation of the IL-6-
gp130-STAT3 signaling axis in type I collagen+ nonhemato-
poietic cells increased IL-7 expression (Sawa et al., 2006). This
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proliferation, which was directly associated with the develop-
ment of autoimmune arthritis in F759 mice (Sawa et al., 2006).
Our results suggested that extrinsic stimuli, such as TLR
signaling, can regulate IL-7 production under normal conditions
in vivo. To examine this possibility, we investigated serum IL-7
amounts after LPS stimulation. We first enhanced the sensitiv-
ities of an IL-7-specific ELISA kit and immunoblotting system,
in which IL-7 was detected with a commercially available anti-
body (Figure S1 available online; see Experimental Procedures).
We found that mice injected with LPS showed increased serum
amounts of IL-7 (Figure 1A; Figure S1A). The results showed that
the serum concentration of IL-7 peaked 12 hr after LPS treat-
ment (data not shown).
To identify the major source(s) of IL-7 after LPS injection, we
examined the expression of IL-7 mRNA in various organs before
and after LPS treatment by using real-time PCR. LPS induced an
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Figure 1. LPS Injection Induces IL-7 Pro-
duction in the Liver
(A) IL-7 in serum was detected with immunoblot-
ting 12 hr after LPS treatment. The arrow denotes
the expected size of the IL-7 band.
(B) IL-7 mRNA expression in various organs after
treatment with LPS. Organs were harvested from
mice 6 hr after they were treated with or without
LPS (n = 6 for spleen, n = 4 for lymph nodes [LN],
n = 10 for liver, n = 14 for kidney, n = 6 for heart, n = 6
for lung, n = 6 for thymus, n = 4 for muscle, n = 4 for
bone marrow [BM], and n = 4 for skin). IL-7 mRNA
expression was measured by real-time PCRs. After
LPS treatment, IL-7 expression in the spleen and
lymph nodes significantly decreased, whereas it
significantly increased in the liver and kidney (p =
0.0026, 0.042, 0.000011, and 0.0030, respectively).
(C) IL-7 mRNA expressions in liver and kidney
tissues with or without LPS treatment were
measured by real-time PCRs. The levels of IL-7
mRNA in the liver tissue 6 hr after treatment and
in the kidney tissue 3 and 6 hr after treatment
were significantly higher thanbefore LPS treatment
(p = 0.021, 0.000064, and 0.0023, respectively).
(D) The estimated amounts of IL-7 mRNA were
calculated with the real-time PCR results from
(C) and the average organ weights. After LPS
treatment, IL-7 expression in the spleen signifi-
cantly decreased, whereas it significantly
increased in the liver and kidneys (p = 0.0026,
0.000011, and 0.003, respectively).
(E) IL-7 expression was analyzed in serum isolated
from hepatectomized mice or sham-operated
animals before and 12 hr after LPS treatment
(n = 5 each). Representative data are shown.
(F) IL-7 in liver 12 hr after LPS treatment was de-
tected with immunoblotting.
For (B)–(D), data represent the mean + SD; *p <
0.05 compared with control samples.
increase in the expression of IL-7 mRNA
in kidney and liver tissues, whereas
expression decreased in the spleen and
lymph nodes in response to LPS
(Figure 1B). On the other hand, LPS did
not substantially affect IL-7 expression in other organs, including
heart, thymus, lung, skin, and muscle (Figure 1B), suggesting
that IL-7 mRNA expression is differentially regulated by TLR
ligands in the various organs. Time-course experiments
confirmed that the amount of IL-7 mRNA transiently increased
in liver and kidney tissues, peaking 6 hr after the LPS injection
(Figure 1C), whereas it decreased in lymph nodes (Figure S2).
In organs in which the major cell populations produce IL-7 in
response to LPS, the total amount of IL-7 expressed in each
organ should be related to the size of the organ. We estimated
the total amount of expressed IL-7 by using the weight of the
organ (average organ weights in 7- to 8-week-old C57BL/6
mice [n = 5]: spleen, 0.09 g; kidney, 0.32 g; heart, 0.13 g; liver,
0.95 g; thymus, 0.05 g; and lung, 0.14 g). As expected, a larger
relative amount of IL-7 was expressed in the liver than in any of
the other organs after LPS stimulation (Figure 1D). Thus, the liver
appears to be a major source of LPS-induced IL-7 expression.448 Immunity 30, 447–457, March 20, 2009 ª2009 Elsevier Inc.
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Figure 2. IL-7 Expression Is Induced in
Hepatocytes after LPS Injection In Vivo
(A) Myd88/, Ticam1/, and control wild-type
mice (n = 5 each) were injected with LPS and the
livers were harvested 6 hr later. IL-7 mRNA expres-
sion in the livers was analyzedwith real-time PCRs.
After treatment with LPS, the expression of IL-7
mRNA in the Ticam1/ mice was lower than in
the wild-type controls (p = 0.046).
(B) Serum expressions of IL-7 were examined in
Myd88/, Ticam1/, and control animals with
or without LPS via immunoblotting 12 hr after injec-
tions.
(C) Ifnar1/ and control mice (n = 5 each) were in-
jected with LPS and the livers were harvested. IL-7
mRNA expression was analyzed with real-time
PCR. 6 hr after LPS treatment, the expression of
IL-7 mRNA in the IFN-I receptor-deficient mice
was lower than in wild-type controls (p = 0.038).
(D) IL-7 mRNA in liver with or without TLR ligand
treatment were measured with real-time PCRs.
The IL-7 mRNA in liver increased 6 hr after treat-
ment with LPS (2.5 mg), CpG (25 mg), poly(I-C)
(100 mg), imiquimod (25 mg), or zymosan (500 mg)
(p = 0.002, 0.0036, 0.00035, 0.0017, and 0.012,
respectively).
(E) IL-7mRNA in the liver with or without TLR ligand
treatment were measured in IFN-I receptor-defi-
cient mice or control animals by real-time PCRs.
The IL-7 mRNA in the liver were lower in IFN-I
receptor-deficient mice than in control mice 6 hr
after treatment with CpG (25 mg), poly(I-C)
(100 mg), or imiquimod (25 mg) (p = 3.2 3 108,
3.7 3 107, and 6.3 3 106, respectively).
(F) IL-7 expression in primary hepatocytes was
significantly elevated 6 hr after treatment with
IFN-b (p = 0.00022). Data represent the mean +
SD; *p < 0.05 compared with control samples;
N.S., not significant.Weconfirmed the important roleof liver tissues inLPS-mediated
upregulationof serum IL-7byusingpartial hepatectomies (Mitchell
and Willenbring, 2008). We showed that the LPS-mediated
increases in serum IL-7 were smaller in mice that underwent
hepatectomy than in sham-operated animals (Figure 1E).
Importantly, IL-7 protein expression increased in liver cells after
LPS stimulation (Figure 1F). Thus, we concluded that liver is the
major source of LPS-induced IL-7 expression.
Hepatic IL-7 Expression Is Dependent on TRIF-IFN-I
Pathway after LPS Injection In Vivo
LPSsignaling can occur through either of two adaptormolecules,
TRIF or Myd88, both of which intracellularly bind to the LPS
receptor TLR4 (Yamamoto et al., 2003). To investigate which of
these pathways is important for LPS-mediated IL-7 expression
in liver tissues, we employed two mouse strains: Ticam1/
(TRIF-deficient) and Myd88/ mice (Adachi et al., 1998;
Yamamoto et al., 2003). IL-7 expression markedly increased in
Myd88/ and wild-type control liver tissues and sera but not in
Ticam1/ livers after LPS treatment (Figures 2A and 2B). Toinvestigate whether IFN-I, a target of the TRIF-dependent
pathway, is critical for the induction of IL-7 expression in the liver
after LPS injection, we prepared Ifnar1/ mice (Mu¨ller et al.,
1994). Although LPS injection increased IL-7 mRNA expression
in the livers of wild-type mice, this effect was not observed in
Ifnar1/ mice (Figure 2C). Collectively, these results demon-
strated that LPS-mediated upregulation of IL-7 expression in
the liver is dependent on the TRIF-IFN-I signaling pathway.
To determine whether IL-7 expression in the liver is generally
induced by TLR signaling, which is known to increase the
expression of IFN-I, we treated mice with various TLR ligands,
including CpG, poly(I-C), imiquimod, and zymosan, to mimic
physiologic responses to infection. All of the tested TLR ligands
increased IL-7 expression in liver tissues (Figure 2D). Further-
more, we investigated whether CpG-, imiquimod-, zymosan-,
and poly(I-C)-mediated upregulation of IL-7 expression in the
liver was dependent on IFN-I by using mice deficient for the
IFN-I receptor. The results showed that the increased IL-7
expression induced in the liver by each of the TLR ligands except
zymosan was dependent on IFN-I (Figure 2E).Immunity 30, 447–457, March 20, 2009 ª2009 Elsevier Inc. 449
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Hepatic IL-7 Regulates T Cell ResponsesBecause the liver contains a number of cell types that poten-
tially could serve as sources of IL-7, including stromal cells,
dendritic cells, Kupffer cells, natural killer (NK) cells, NK T cells,
conventional T cells, and hepatocytes, we next sought to deter-
mine which cells in the liver produce IL-7 in response to LPS. We
obtained a primary culture of mouse hepatocytes and stimulated
the cells with LPS or IFN-I (IFN-b). We found that IFN-b but not
LPS markedly induced the expression of IL-7 mRNA in the
primary hepatocytes (Figure 2F). These results strongly sug-
gested that IFN-b, which is upregulated via LPS-TRIF signaling
in nonhepatocytes, induces IL-7 expression in hepatocytes.
Thus, IL-7 is likely an acute-phase reactant expressed in
response to TLR-IFN-I signaling in hepatocytes.
Depletion of IL-7 Expression in the Liver Reduces
Memory and Naive CD4+ and CD8+ T Cells
To uncover a direct link between the IL-7 expression induced via
TLR-IFN-I signaling and T cell responses in vivo, we attempted to
deplete IL-7 expression in hepatocytes by using hydrodynamics-
based transfection of plasmid DNA (Zhang et al., 1999). It has
been reported that the transduction of genes by this method
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D Figure 3. Liver-Specific IL-7 Depletion in
Mice
C57BL/6 mice were treated with plasmid vectors
coding for IL-7 shRNA or scrambled control
shRNA. The mice were then injected with LPS
and the IL-7 mRNA expression in the liver (A) and
other organs (D) were analyzed 6 hr after the injec-
tion with real-time PCRs. The amount of LPS-
mediated IL-7 expression in liver was lower in the
mice treated with IL-7 shRNA (n = 20 for scrambled
shRNA plus LPS and n = 20 for other conditions;
p = 0.005). (B) IL-7 in serum 12 hr after LPS treat-
ment, (C) IL-7 in the liver 12 hr after LPS treatment,
and (E) IL-7 in other organs 12 hr after LPS treat-
ment were detected with immunoblotting. Data
represent the mean + SD; *p < 0.05 compared
with control samples.
results in increased gene transfection
efficacy and higher target molecule
expression in hepatocytes than in other
cell types. In fact, this method produces
a degree of expression that is more than
three orders of magnitude higher in liver
cells than in other organs, including
kidney, spleen, thymus, lymph nodes,
muscle, lung, skin, and heart (Figure S3
and data not shown; Zhang et al., 1999).
Plasmids coding for either IL-7-specific
short hairpin RNA (shRNA) or a scrambled
control sequence were introduced into
liver cells by this transfection method.
After LPS injection, IL-7 mRNA and
protein expression in the liver as well as
the serum amount of IL-7 protein was
lower inmice transfectedwith the plasmid
coding for IL-7 shRNA compared with
mice treated with the plasmid coding for
scrambled control shRNA (Figures 3A–3C). We also confirmed
that the expression of IL-7 in other organs, including lymph
nodes, spleen, lung, heart, thymus, and kidney, was not affected
markedly by the injection of the IL-7 shRNA plasmid (Figures 3D
and 3E). These results demonstrated that the hydrodynamics-
based transfection of a plasmid coding for IL-7 shRNA specifi-
cally depleted the expression of IL-7 protein in hepatocytes
in vivo.
By using the hydrodynamics-based transfection method, we
evaluated the physiological roles of TLR-IFN-I-mediated expres-
sion of IL-7 in immune cell responses. We first investigated the
sizes of various cell populations before and after LPS-TLR stim-
ulation in the presence or absence of hepatocyte-specific deple-
tion of IL-7 expression. LPS-TLR stimulation increased the
numbers of CD4+ T cells, CD8+ T cells, NK cells, B cells, and
granulocytes, whereas the dendritic cell population was not
affected (Figures S4A and S4B). Importantly, TLR-mediated
hepatic IL-7 expression only increased the CD4+ and CD8+
T cell numbers but not those of NK cells, B cells, and granulo-
cytes (Figures S4A and S4B). Moreover, the populations of
both naive and memory CD4+ and CD8+ T cells expanded in450 Immunity 30, 447–457, March 20, 2009 ª2009 Elsevier Inc.
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Hepatic IL-7 Regulates T Cell Responsesresponse to TLR-induced hepatic IL-7 expression (Figure 4A;
Figure S4A). Time-course experiments showed that the T cell
number peaked on day 3 after LPS injection (Figure 4A). After
LPS treatment, a larger increase in the T cell number was
observed in liver tissues than in lymphoid tissues (Figure 4B).
Further, expansion of the T cell population was dependent on
A B
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Figure 4. CD4+ and CD8+ T Cell Numbers Increase in Response to
LPS-Induced IL-7 Production in the Liver
C57BL/6 mice were treated with plasmid vectors coding for IL-7 shRNA or
scrambled control shRNA 1 day before LPS injection. The mice were then
intraperitoneally injected with LPS (2.5 mg). (A) The numbers of CD4+ and
CD8+ T cells in lymph nodes and spleen or liver, (B) the numbers of CD44hi cells
among the CD8+ and CD4+ T cells in lymph nodes and spleen or liver, and (C)
the numbers of CD4+CD25+ cells in lymph nodes and spleen were analyzed on
days 0, 1, 3, and 6 after LPS injection with a flow cytometer. LPS treatment
increased the numbers of CD4+ and CD8+ T cells in lymph nodes (A), spleen
(A), and liver (B); the numbers of memory CD44hi cells among the CD8+ and
CD4+ T cells in the lymph nodes (A), spleen (A), and liver (B); and the numbers
of memory CD4+CD25+Foxp3+ cells in the lymph nodes and spleen (C). The
numbers of CD4+, CD8+, CD4+CD44hi, and CD8+CD44hi T cells on day 3 after
the LPS stimulation were significantly lower in mice treated with IL-7 shRNA
compared with mice injected with scrambled control shRNA (p = 0.0164,
0.00249, 0.0124, and 0.00049, respectively [A]; p = 0.0001, 0.0062, 0.00017,
and 0.048, respectively [B]). The numbers of CD4+CD25+Foxp3+ T cells on
day 3 after the LPS stimulation were significantly lower in mice treated with
IL-7 shRNA than in mice treated with scrambled control shRNA (p = 0.049)
(C). Data represent the mean + SD; *p < 0.05 compared with control samples.IL-7 expression (Figures 4A and 4B). Upregulation of IL-7 expres-
sion in the liver also expanded the Treg cell (CD4+CD25+Foxp3+
T cells) population in vivo (Figure 4C).
We then examined whether activation markers of T cells, such
as CD69 and CD44, were regulated by TLR-IFN-I-mediated
hepatic IL-7 expression. The percentage of CD69+ T cells among
the CD4+ and CD8+ T cells increased after LPS treatment,
whereas that of CD44+ T cells did not (Figure S5). Furthermore,
TLR-induced hepatic IL-7 expression did not contribute to the
increased percentage of CD69+ T cells (Figure S5).
Because it is known that IFN-I is pleiotropic, serving both
suppressive and stimulatory functions at various points during
T cell immune responses in vivo (Theofilopoulos et al., 2005),
we examined the specific contributions of IFN-I to IL-7-mediated
increases in T cell numbers in the liver. We prepared mice with
depleted IFN-I receptor expression in their livers and injected
them with LPS; the LPS-mediated increases in serum IL-7 and
the T cell number were dependent on IFN-I receptors in the liver
(data not shown and Figure 5). These data suggest that IFN-I
functions to enhance T cell-mediated adaptive immunity in the
liver via IL-7.
We next investigated whether TLR-IFN-I-induced hepatic IL-7
expression increased the T cell number by enhancing the prolif-
eration or survival of T cells. BrdU was placed in the drinking
water of the mice to allow us to examine the percentage of prolif-
erating T cells before and after LPS treatment in the presence or
absence of IL-7 depletion in the liver. LPS treatment increased
Figure 5. CD4+ and CD8+ T Cell Numbers Increase in Response to
LPS-Mediated IFN-I Signaling in the Liver
C57BL/6 mice were treated with plasmid vectors coding for IFN-I receptor
shRNA or scrambled control shRNA 1 day before LPS injection. The mice
were then intraperitoneally injected with LPS (2.5 mg) and the CD4+ and
CD8+ T cells, and the CD44hi cells among the CD8+ and CD4+ T cells were
counted. On day 3 after LPS stimulation, the numbers of CD4+, CD8+,
CD4+CD44hi, and CD8+CD44hi T cells were significantly lower in mice treated
with IFN-I receptor shRNA compared with mice injected with scrambled
control shRNA (p = 0.0054, 0.00093, 0.0016, and 0.0052, respectively). Data
represent the mean + SD; *p < 0.05 compared with control samples.Immunity 30, 447–457, March 20, 2009 ª2009 Elsevier Inc. 451
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T cells but not that of BrdU+ naive-phenotype CD8+ T cells
(Figure S6); the populations of both BrdU+ memory- and naive-
phenotype CD4+ T cells also did not expand, as demonstrated
previously (Sun et al., 1998; Tough et al., 1996). Moreover,
LPS-mediated hepatic IL-7 expression did not markedly
contribute to the increase in the number of proliferating BrdU+
memory-phenotype CD8+ T cells (Figure S6). These results
strongly suggested that TLR-IFN-I-induced hepatic IL-7 expres-
sion increased the numbers of naive and memory CD4+ and
CD8+ T cells by enhancing their survival.
Hepatic IL-7 Expression Induced via LPS Signaling Plays
a Role in CD8+ and CD4+ T Cell Responses
To examine the relationship between increased hepatic IL-7
expression and T cell responses, we first performed infection
experiments with Listeria and LCMV to investigate antigen-
specific CD8+ T cell responses with or without depleted IL-7
expression in the liver. By using Listeria and LCMV, we showed
that upregulated IL-7 expression in the liver does not markedly
contribute to pathogen-specific CD8+ T cell proliferation
(Figure S7). We also confirmed that the liver showed high
amounts of IL-7 mRNA expression in response to both infec-
tions, and that IL-7 shRNA but not scrambled control shRNA
effectively attenuated observed hepatic IL-7 mRNA expression
(Figure S8). Consistent with these results, it was reported that
IL-7 signaling is dispensable for antigen-induced expansion of
the CD8+ T cell population, whereas it is essential for CD8+
memory T cell production (Schluns et al., 2000). Additionally,
we showed that the Listeria-specific and the LCMV-specific
CD4+ T cells were not affected by the hepatically expressed
IL-7 (Figure S9 and data not shown).
IFN-I has been shown to induce an increase in the number of
CD44hi memory-activated T cells, a process referred to as
bystander activation (Marrack et al., 1999). This IFN-I-dependent
increase in the memory T cell population occurs independently
of signaling through the T cell receptor (TCR) and is believed to
play a role in long-lasting memory T cell maintenance in the
absence of specific antigen (Kolumam et al., 2005). Therefore,
we examined the involvement of TLR-IFN-I-mediated IL-7
expression in the prolongation of antigen-specific responses.
LPS treatment increased the number of antigen-specific
memory-activated CD8+ T cells, whereas depletion of IL-7
expression in hepatocytes suppressed these effects (Figure 6A;
Figure S10). Moreover, cytotoxic T-lymphocyte (CTL) activity
and IFN-g expression in the CD8+ T cells were higher in mice
treated with LPS than in untreated mice (Figures 6B and 6C).
Importantly, IL-7 depletion in the liver cells inhibited the LPS-
mediated enhancement of CTL activity and IFN-g expression
(Figures 6B and 6C).
We next investigated whether hepatic IL-7 expression in
response to LPS plays a role in the homeostatic proliferation of
CD8+ T cells under lymphopenic conditions, which are known
to increase the number ofmemory-activated CD8+ T cells. As ex-
pected, CD8+ T cell homeostatic proliferation was enhanced by
upregulated IL-7 expression in the liver (Figures 6D and 6E).
Taken together, these results demonstrated that the upregulation
of IL-7 expression in the liver increases the number of memory-
activated CD8+ T cells in an antigen-nonspecific manner.452 Immunity 30, 447–457, March 20, 2009 ª2009 Elsevier Inc.To investigate the role of TLR-induced hepatic IL-7 expression
in the development of CD4+ T cell responses, we employed an
experimental autoimmune encephalomyelitis (EAE) system, in
which mice develop a Th17 cell- and Th1 cell-mediated autoim-
mune disease; in this model, the percentages of IL-17- and IFN-
g-expressing CD4+ T cells are determinants of disease severity
(Stromnes et al., 2008). EAE was induced with MOG peptides in
addition to the TLR ligands pertussis toxin (PTx) to stimulate
TLR4 and/or complete Freund’s adjuvant (CFA) to stimulate
TLR2 and TLR4 (Jo et al., 2007; Racke et al., 2005). We hypothe-
sized that TLR-induced hepatic IL-7 expression enhances patho-
genic CD4+ T cell responses, because IL-7 expression increased
after treatment with PTx and/or CFA (data not shown), and the
serum IFN-I concentration increased after immunization with
the peptide (Figure 7A). Th17 cell numbers and serum expression
of IL-17 in the EAE mice were then examined in the presence or
absence of the IL-7 shRNA plasmid. Depletion of IL-7 expression
in the liver decreased the numbers of Th17 and Th1 cells in both
the spinal cord and draining lymph nodes (Figures 7B and 7C), as
well as the serum concentrations of IL-17 and IFN-g (Figure 7D).
Thus, these results strongly suggest that hepatically derived IL-7
contributes to the induction of pathogenic CD4+ T cell responses
associated with EAE. Importantly, the IL-7 deficiency attenuated
the development of EAE (Figure 7E).
DISCUSSION
We have demonstrated that both CD4+ and CD8+ T cell
responses are enhanced by TLR-mediated increases in hepatic
IL-7 expression in vivo. It was previously thought that the degree
of intracellular IL-7-mediated signaling depends primarily on the
amount of IL-7Ra expressed on the cell surface (Mazzucchelli
andDurum, 2007; Schluns et al., 2000).Moreover, IL-7 is thought
to be expressed at a constant amount in vivo, unaffected by
extrinsic stimulation (Fry and Mackall, 2005). Therefore, many
studies have focused on the expression of the receptor rather
than the ligand. Indeed, memory-activated T cells have been
shown to express high amount of IL-7Ra (Kaech et al., 2003).
However, we recently showed that excessive IL-7 production
in nonhematopoietic cells from F759 mutant mice, which show
augmented IL-6-gp130-STAT3 signaling, contributes to the
development of autoimmune arthritis (Atsumi et al., 2002;
Sawa et al., 2006). Moreover, our results here demonstrate
that IL-7 production induced via TLR-IFN-I signaling in wild-
type mice contributes to T cell survival and enhanced T cell
responses. Thus, intensity of IL-7 signaling in T cells is depen-
dent on both the amount of IL-7, which is regulated by such
signaling pathways as IL-6-gp130-STAT3 and TLR-IFN-I, and
the expression of IL-7Ra, which is controlled by various signaling
molecules, including TCRs and cytokines.
We have also shown that the liver is a primary source of IL-7 in
response to TLR stimulation, although IL-7 expression is limited
in the liver under steady-state conditions. TLR-mediated
systemic cytokine expression alters protein expression profiles
in hepatocytes, which produce a number of serum acute-phase
reactant proteins, markers of systemic inflammation that include
SAA, CRP, plasminogen, ferritin, and complement components
(Fey et al., 1994). Thus, IL-7, an important survival factor for
T cells, is expressed in the liver in response to inflammation to
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Figure 6. CD8+ T Cell Responses Are Regu-
lated by LPS-Mediated IL-7 Production in
the Liver
(A–C) OT-1 CD8+ T cells were transferred to con-
genic mice and activated with OVA and CFA. 4
days after activation, CD8+CD44hiCD90.2+ T cells
were sorted and transferred to B6.PL mice
(day 0). The mice were then treated with LPS
(days 0, 2, 4, and 6) and IL-7 shRNA or scrambled
control shRNA (days 1, 1, 3, and 5). OT-1 CD8+
T cell numbers and CTL activity were measured
on day 8. In the presence of LPS, significant
decreases in the number of OT-1 T cells (A), in the
in vivo CTL activity (B), and in the number of
CD90.2+IFNg+OT-1 T cells (C) were observed after
treatment with IL-7 shRNA compared with results
observed after treatment with scrambled control
shRNA (p = 0.015, 0.017, and 0.01, respectively).
(D) Carboxyfluorescein diacetate succinimidyl
ester (CFSE)-labeled CD8+CD44lo T cells from
C57BL6-SJL (CD45.1) were transferred to suble-
thally irradiated (5 Gy) C57BL/6 mice and the
mice were treated with IL-7 shRNA or scrambled
control shRNA in the presence or absence of
LPS. Proliferation of the transferred CD8+CD45.1+
T cells was assessed by FACS-measured dilution
of CFSE. We have divided the CFSE-labeled cells
into three populations: nondividing (high CFSE
concentration), slowly dividing (1 to 4 divisions;
midlevel CFSE concentration), and rapidly dividing
(more than 5 divisions; low CFSE concentration).
The numbers represent the percentage of cells in
these populations.
(E) The actual cell numbers in each population from
(D): nondividing, white columns; slowly dividing,
gray columns; rapidly dividing, black columns. In
the presence of LPS, a larger increase in the rapidly
dividing population was observed for CD8+ T cells
from mice treated with scrambled control shRNA
than for those from mice treated with IL-7 shRNA
(p = 0.021). Data represent the mean + SD; *p <
0.05 compared with control samples.allow the immune system to respond against pathogens as an
acute-phase reactant. It should be noted that IL-7 expression
increased only in liver and kidney tissues after TLR stimulation,
whereas it decreased in the spleen and lymph nodes. These
results suggested that systemic IL-7 expression driven by hepa-
tocytes, but not by lymphoid organs, play an important role in
IL-7-mediated T cell homeostasis in response to infections.
How IL-7 expression is differentially regulated in the different
organs after TLR activation, however, has not yet been eluci-
dated. Interestingly, IL-7 transgenic mice develop autoimmune
diseases, such as colitis (Watanabe et al., 1998) and dermatitis
(Uehira et al., 1998). Because T cells in lymphoid organs are acti-
vated by the systemic expression of IL-7 in IL-7 transgenic mice
even under steady-state conditions (Watanabe et al., 1998),
heightened IL-7 expression in lymphoid organs likely leads to
an increased number of autoreactive T cells and autoimmune
diseases. Thus, the decreased IL-7 expression in lymphoid
organs after TLR stimulation may counteract these processes.
IL-7 expression in hepatocytes is critical for enhanced
antigen-specific CD8+ T cell responses, a process that occurs
via antigen-nonspecific bystander proliferation. Moreover, thefact that hepatic IL-7 expression was induced by all of the tested
TLR ligands may be advantageous for vaccine development,
because the use of TLR ligand combinations synergistically
increases the intensity of signaling followed by enhanced cyto-
kine expression (Napolitani et al., 2005). TLR ligand combina-
tions also may synergistically increase the amount of IL-7
expression from hepatocytes, which would enhance antigen-
specific memory and activated T cell responses. Treatment
with TLR ligands after a period of antigen-specific T cell activa-
tion, a contraction phase and/or a memory phase, would effi-
ciently increase memory-activated T cell responses, because
increased IL-7 expression in the liver did not play a major role
in the proliferation of antigen-specific CD8+ T cells in response
to Listeria and LCMV at a period of antigen-specific T cell activa-
tion. Future studies about these issues may increase the effica-
cies of vaccines in vivo through a hepatic IL-7-dependent
enhancement of memory-activated T cell maintenance. Regula-
tion of IL-7 production in the liver must be tightly controlled,
however, because IL-7 expression in hepatocytes contributes
to the induction of pathogenic T cell activity and may enhance
autoimmune diseases, such as EAE.Immunity 30, 447–457, March 20, 2009 ª2009 Elsevier Inc. 453
Immunity
Hepatic IL-7 Regulates T Cell ResponsesA
B
C
D
E
Figure 7. CD4+ T Cell Responses Are Regulated by LPS-Mediated
IL-7 Production in the Liver
(A) C57BL/6 mice were injected with MOG peptide and CFA (day 0) and intra-
venously with PTx (days 0, 2, and 7). IFN-b concentrations in serum were
measured 12 hr after the last PTx injection in immunized C57BL/6 mice and
compared with results observed in control nonimmunized mice (p = 0.0054).
(B and C) C57BL/6 mice treated with IL-7 shRNA or scrambled control shRNA
(days 1, 1, and 6) were injected subcutaneously with MOG peptide and CFA
(day 0) followed by intravenous injection of PTx (days 0, 2, and 7). (B) CD4+
T cells from the inguinal lymph nodes of immunized C57BL/6 mice were sorted
with magnetic beads on day 10 and (C) mononuclear cells from the spinal
cords of immunized C57BL/6 mice were isolated on day 21. The resulting
cell populations were stimulated in vitro with MOG peptide and bone
marrow-derived dendritic cells. 6 hr after in vitro stimulation, intracellular
IL-17 and IFN-g were examined. The CD4+IL-17+ and CD4+IFN-g+ T cells
from immunized C57BL/6 mice treated with IL-7 shRNA or scrambled control
shRNA were counted (days 1, 1, and 6). The numbers of CD4+IL-17+ and
CD4+IFN-g+ T cells in the inguinal lymph nodes (p = 0.00299 and 0.00362,
respectively) and the spinal cords (p = 0.00491 and 0.0147, respectively)
were significantly lower in the immunized mice treated with IL-7 shRNA than
in those treated with scrambled control shRNA.
(D) C57BL/6 mice treated with IL-7 shRNA or scrambled control shRNA
(days 1, 1, and 6) were injected subcutaneously with MOG peptide and
CFA (day 0) followed by intravenous injection of PTx (days 0, 2, and 7). On
day 10, the serum IL-17A and IFN-g concentrations were significantly lower
in the immunized mice treated with IL-7 shRNA than in those treated with
scrambled control shRNA (p = 0.0026 and 0.000479, respectively).
(E) C57BL/6 mice treated with IL-7 shRNA or scrambled control shRNA
(days 1, 1, and 6) were injected subcutaneously with MOG peptide and
CFA (day 0) followed by intravenous injection of PTx (days 0, 2, and 7) and anal-
ysis for EAE development. EAE development was attenuated in the C57BL6
mice injected with IL-7 shRNA compared with mice injected with scrambled454 Immunity 30, 447–457, March 20, 2009 ª2009 Elsevier Inc.TLR-mediated hepatic IL-7 expression was dependent on
IFN-I. The role of IFN-I in T cell responses is complicated. IFN-I
may play contradictory roles in the regulation of immune
responses, especially for the development of autoimmune
diseases; this cytokine enhances several autoimmune diseases
(Stewart et al., 1993), whereas it suppresses others (Treschow
et al., 2005). In humans, one of the most commonly used thera-
pies for multiple sclerosis is systemic administration of IFN-I, in
particular IFN-b. In patients with multiple sclerosis, IFN-b has
been shown to reduce the frequency of clinical exacerbations,
the progression of disability, and cumulative disease activity.
Despite these clinical benefits, however, IFN-b is only partially
effective and is not a cure for multiple sclerosis. Furthermore,
many patients do not respond to this treatment modality.
Because IFN-I treatment may produce an unwanted augmenta-
tion of IFN-I-IL-7 signaling, as demonstrated here, targeting the
TLR-IFN-I-IL-7 signaling axis may provide an effective thera-
peutic approach for autoimmune diseases, including multiple
sclerosis.
In summary, we identified hepatically derived IL-7 as an
effecter molecule of TLR-IFN-I-mediated signaling in vivo. The
TLR-IFN-I-IL-7 signaling axis in the liver, which was found to
contribute to increased numbers of naive and memory CD4+
and CD8+ T cells, enhances LPS-mediated increases in the
antigen-specific memory-activated CD8+ T cell number,
antigen-specific CTL activity, and EAE, a CD4+ T cell-induced
autoimmune disease. Thus, we concluded that the induction of
IL-7 expression in liver cells via TLR-IFN-I signaling is important
for T cell responses and subsequent enhancement of adaptive
immunity in vivo.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice were purchased from Japan SLC. B6.PL (Thy-1.1) congenic
mice were purchased from the Jackson Laboratory. B6.SJL (CD45.1) con-
genic mice were obtained from Taconic. C57BL/6-Myd88-deficient (Adachi
et al., 1998) and C57BL/6-TRIF-deficient (Yamamoto et al., 2003) mice were
obtained from S. Akira (Osaka University, Japan). IFN-I receptor-deficient
mice were obtained from T. Kaisho (RIKEN-RCAI, Japan). C57BL/6-OT-1
TCR transgenic mice were kindly provided by W. Heath (WEHI, Australia).
Mice were maintained in the medical science animal facilities at Osaka Univer-
sity under specific pathogen-free conditions (SPF). Animal experiments were
performed according to the guidelines of the Institutional Animal Care and
Use Committees of the Graduate School of Frontier Biosciences and theGrad-
uate School of Medicine (Osaka University). We used 7- to 12-week-old
animals for all of the experiments.
Antibodies and Reagents
FITC-conjugated anti-mouse CD19, NK1.1, I-Ab, Gr-1, CD44, Foxp3, and
IgG2a; PE-conjugated anti-mouse CD4, Dx5, CD69, CD44, IL-17A, IgG2a,
and CD25; PE-Cy5-conjugated anti-mouse CD4 and CD8; PE-Cy7-conju-
gated anti-mouse CD4 and CD8; APC-conjugated anti-mouse CD8, CD90.1,
and CD45.1; PB-conjugated anti-mouse CD44; biotin-conjugated anti-mouse
CD8; and APC-conjugated streptavidin were purchased from eBioscience.
FITC-conjugated anti-mouse CD4 and CD8; APC-conjugated anti-mouse
CD4, IFN-g, and IgG1; biotin-conjugated anti-mouse CD19, Dx5, TCRb, and
control shRNA (p = 0.003, 0.002, and 0.003 on days 22, 24, and 26 after the
first immunization, respectively). All data are shown as the mean + SD, except
for the T cell numbers in the spinal cord (C) and EAE development (E) (mean +
SEM). *p < 0.05 compared with control samples.
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FITC-conjugated anti-mouse BrdU, PE-conjugated anti-mouse IFN-g, IgG1,
and APC-conjugated anti-mouse CD90.2 were purchased from BD Biosci-
ences. PE-conjugated DbGP33 tetramer and H-2Kb OVA tetramer were
used. Anti-mouse actin was purchased from Santa Cruz Biotechnology.
HRP-conjugated anti-mouse IgG was purchased from Zymed Laboratories.
LPS, poly(I-C), and partially purified zymosan were purchased from Sigma.
CpG was obtained from Operon and imiquimod was purchased from
InvivoGen.
IL-7 ELISA
Precoated plates from an IL-7 ELISA kit (R&D Systems) were blocked with 13
ELISAUltrablock (AbD Serotec) for 3 hr and 1503 human serum for 3 hr at 4C.
The plates were then washed three times with PBS containing 0.05% Tween-
20 (PBST). Then, samples were applied to the resulting plates (overnight at
4C), washed five times with PBST, and incubated with biotin-labeled poly-
clonal IL-7 antibodies (R&D Systems) overnight at 4C followed by treatment
with 10 mg/ml polyHRP80 (Stereospecific Detection Technologies). The sensi-
tivity of the ELISA system was determined with a titration of rIL-7 (Peprotech;
Figure S1B). IL-7 was not detected in the sera of normal C57BL/6 mice and
IL-7-deficient mice kept under SPF conditions (less than 8 pg/ml). The speci-
ficity of the system was confirmed by two methods. First, both intravenous
injection of rIL-7 and IL-7 expression in hepatocytes after hydrodynamics-
based transfection resulted in an increased serum IL-7 concentration (data
not shown). Second, supernatants from L929 cells transfected with cDNA
encoding murine IL-7 were found to contain approximately 20 pg/ml mIL-7,
whereas those from mock-transfected L929 cells did not contain a detectable
level (less than 8 pg/ml; data not shown).
Immunoblotting for IL-7
Mice sera were collected and concentrated as described previously (Sawa
et al., 2006). The concentrated sera weremixed with SDS buffer. Western blot-
ting for IL-7 was performed as described previously (Sawa et al., 2006). After
SDS-PAGE on a 10%–20% gel, the protein fraction was used for western blot-
ting analysis with biotinylated anti-mouse IL-7 antibodies (R&D Systems; the
same antibody used as the detector antibody for the IL-7 ELISA system) and
streptavidin-conjugated horseradish peroxidase secondary antibodies
(Sigma). The samples were visualized with an enhanced chemiluminescence
kit (Perkin Elmer). The sensitivity of the immunoblot system was determined
with a titration of rIL-7 (Peprotech) (Figure S1C). IL-7 was not detected in the
sera of normal C57BL/6 mice (less than 5–10 pg/ml). The sensitivity of the
IL-7 western blotting system was similar to that of the IL-7 ELISA system.
The specificity of the system was confirmed with the same two methods
described for the ELISA system.
IL-7 immunoblotting with organ samples yielded similar results to those
observed with serum samples. In brief, liver, spleen, thymus, and kidney cells
were minced, homogenized in hypotonic buffer (10 mM Tris-HCl, 1 mMMgCl2,
0.25 M sucrose, and 1% protease inhibitor at pH 7.4 [Nacalai Tesque]), and
centrifuged. The resulting supernatants from spleen and thymus were sub-
jected to SDS-PAGE followed by immunoblotting. The resulting supernatants
from liver and kidneywere subjected to immunoprecipitation with IL-7-specific
monoclonal antibodies (M25) and protein G Sepharose. Then, the immunopre-
cipitants were separated with SDS-PAGE followed by immunoblotting.
Cell Preparation and Cell Sorting
A T cell-enriched sample was prepared with a MoFlo high-performance cell
sorter (Beckman Coulter) as described previously (Ogura et al., 2008). The
purities of the T cell samples were routinely >98%.
Flow Cytometry
Flow cytometry analysis was performed as described previously (Ogura et al.,
2008).
Intracellular Cytokine Staining
The in vivo numbers ofMOG-specific IL-17+ and IFN-g+ T cells andOT-1 IFN-g+
T cells were determined with intracellular cytokine staining as previously
described (Nishihara et al., 2007).ELISA
IFN-b, IL-17A, and IFN-g levels in serum were determined with ELISA kits (BD
Biosciences, eBiosciences, or R&D).
BrdU Labeling
Mice were given 0.8 mg/ml BrdU (Sigma) in their drinking water. BrdU staining
for flow cytometry was performed with a BrdU Flow kit (BD Biosciences).
Generation of Antigen-Specific ActivatedCD8+ TCells and an In Vivo
Cytotoxicity Assay
The lymph nodes and spleen were harvested from OT-1 TCR transgenic mice,
passed through a 100 mm cell strainer with RPMI-1640, and washed. Erythro-
cytes were eliminated with 0.165 M NH4Cl. A T cell-enriched sample was then
prepared with a nylon wool column. The purified cell samples containing 8 3
106 CD8+CD44lo T cells were intravenously injected into B6.PL (CD90.1)
mice on day 1. These mice were then injected with ovalbumin (OVA; Calbio-
chem, Germany) in CFA (Sigma) at the base of the tail on day 0. Activated OT-1
cells (CD8+CD44hiCD90.2+) were sorted on day 4 and injected into B6.PL mice
(2 3 106 cells per mouse). The resulting mice then received an intravenous
injection of shRNA plasmid (10 mg/mouse) with or without LPS (2.5 mg/mouse)
on days 0, 2, 4, and 6 after the transfer of the activated T cells. Splenocytes
from B6 mice were incubated for 30 min at 37C with or without 10 mg/ml
OVA257-264 peptide (Operon Biotechnologies). In vivo cytotoxic activity was
evaluated as described previously (Kamimura et al., 2006).
Real-Time PCRs
Real-time PCRs were performed as described previously (Ogura et al., 2008).
The PCR primer pairs used for real-time PCRs were as follows: mouse HPRT
primers, 50-GATTAGCGATGATGAACCAGGTT-30 and 50-CCTCCCATCTCC
TTCATGACA-30; mouse IL-7 primers, 50-CTGCAGTCCCAGTCATCAGTA-30
and 50-GTGGCACTCAGATGATGTGACA-30. The conditions for the real-time
PCRs were 40 cycles of 94C for 15 s followed by 60C for 60 s. The relative
mRNA expression levels were normalized to the levels of HPRT mRNA.
Primary Hepatocyte Culture and Stimulation
Mouse primary hepatocytes (the purities of the cultures were more than 99%)
were purchased from Cosmo Bio Co. and stimulated with LPS (500 ng/ml;
Sigma) or mouse IFN-b (5 ng/ml; Peprotech) for 6 hr after 12 hr of starvation
in DMEM plus 0.1% FCS.
Construction and Injection of the shRNA Plasmid
RNAi-Ready pSIREN-RetroQ-ZsGreen vector was purchased from Clontech
Laboratories. shRNA plasmid construction was performed according to the
manufacturer’s instructions (IL-7 shRNA sequence: 50-GCCCGAATAATGAAC
CAAACT-30; control shRNA sequence: 50-CGAACACACGAACGACGATA-30;
IFNaRshRNAsequence: 50-GCACATGTGATGGACTCAATT-30; control shRNA
sequence: 50-CAACAAGATGAAGAGCACCAA-30). The resulting shRNA plas-
mids (10 mg) were intravenously injected intomice in 2ml of TransIT-QRHydro-
dynamic Delivery solution (Mirus). We investigated the degree of IL-7 mRNA
knockdown in the liver after a single dose of shRNA to determine the appro-
priate interval between the shRNA injections. We injected mice with IL-7-
specific shRNA on day 0 and stimulated the mice with LPS on days 1, 3, and
7 after the shRNA injection. The inhibition of IL-7 expression peaked on day 1
(approximately 70%–80% suppression) and gradually subsided from day 3
to day 6 (approximately 40%–50% and 10%–20% suppression on day 3 and
day 6, respectively). Therefore, we injected the mice with siRNA every 2 days
during the EAE experiments. Importantly, during the EAE experiments, the
degree of IL-7 mRNA knockdown in the liver remained at approximately
70%–80% on day 25 after immunization, and no marked suppressive effects
were observed in other organs, including the spleen, lung, heart, and kidney
on day 25 after immunization.
Partial Hepatectomy
Two-thirds partial hepatectomies were performed as described previously
(Mitchell and Willenbring, 2008).
Induction of EAE
EAE was induced and scored as described previously (Ogura et al., 2008).Immunity 30, 447–457, March 20, 2009 ª2009 Elsevier Inc. 455
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Mononuclear cells from the spinal cords were isolated after cardiac perfusion
with PBS as described previously (Matsushita et al., 2008). Mononuclear cells
from the livers were isolated after portal vein perfusion with PBS. Liver tissues
were digested with type IV collagenase (0.5 mg/ml; Sigma) at 37C for 30 min.
Mononuclear cells were isolated by passing the tissue through 100 mm cell
strainers (BD Biosciences), followed by Percoll gradient (33%) centrifugation.
After elimination of erythrocytes, lymphocytes were collected from the pellet
and washed.
Statistical Analysis
All comparisons of the data were performed with Student’s t tests (two tails).
SUPPLEMENTAL DATA
Supplemental Data include ten figures and can be found with this article online
at http://www.immunity.com/supplemental/S1074-7613(09)00105-8.
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